EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Cost-Effectiveness of Robot-Assisted Radical Cystectomy vs Open Radical Cystectomy for Patients With Bladder Cancer

Simon Dixon, Harry Hill, Laura Flight, Pramit Khetrapal, Gareth Ambler, Norman R Williams, Chris Brew-Graves, John D Kelly, James W F Catto, iROC Study Team

JAMA Network Open · 30.06.2023 · 6 (6) · e2317255

DOI: 10.1001/jamanetworkopen.2023.17255 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA Network Open, online erschienen am 30.06.2023. Verfasst von Simon Dixon und 9 weiteren Autor:innen. Beteiligte Einrichtung: School of Health and Related Research, University of Sheffield, Sheffield, England. Hauptthemen laut MEDLINE: Robotics, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance The value to payers of robot-assisted radical cystectomy with intracorporeal urinary diversion (iRARC) when compared with open radical cystectomy (ORC) for patients with bladder cancer is unclear.

Objectives

To compare the cost-effectiveness of iRARC with that of ORC. Design, Setting, and Participants This economic evaluation used individual patient data from a randomized clinical trial at 9 surgical centers in the United Kingdom. Patients with nonmetastatic bladder cancer were recruited from March 20, 2017, to January 29, 2020. The analysis used a health service perspective and a 90-day time horizon, with supplementary analyses exploring patient benefits up to 1 year. Deterministic and probabilistic sensitivity analyses were undertaken. Data were analyzed from January 13, 2022, to March 10, 2023.

Interventions

Patients were randomized to receive either iRARC (n = 169) or ORC (n = 169). Main Outcomes and Measures Costs of surgery were calculated using surgery timings and equipment costs, with other hospital data based on counts of activity. Quality-adjusted life-years were calculated from European Quality of Life 5-Dimension 5-Level instrument responses. Prespecified subgroup analyses were undertaken based on patient characteristics and type of diversion.

Results

A total of 305 patients with available outcome data were included in the analysis, with a mean (SD) age of 68.3 (8.1) years, and of whom 241 (79.0%) were men. Robot-assisted radical cystectomy was associated with statistically significant reductions in admissions to intensive therapy (6.35% [95% CI, 0.42%-12.28%]), and readmissions to hospital (14.56% [95% CI, 5.00%-24.11%]), but increases in theater time (31.35 [95% CI, 13.67-49.02] minutes). The additional cost of iRARC per patient was £1124 (95% CI, −£576 to £2824 [US $1622 (95% CI, −$831 to $4075)]) with an associated gain in quality-adjusted life-years of 0.01124 (95% CI, 0.00391-0.01857). The incremental cost-effectiveness ratio was £100 008 (US $144 312) per quality-adjusted life-year gained. Robot-assisted radical cystectomy had a much higher probability of being cost-effective for subgroups defined by age, tumor stage, and performance status. Conclusions and Relevance In this economic evaluation of surgery for patients with bladder cancer, iRARC reduced short-term morbidity and some associated costs. While the resulting cost-effectiveness ratio was in excess of thresholds used by many publicly funded health systems, patient subgroups were identified for which iRARC had a high probability of being cost-effective. Trial Registration ClinicalTrials.gov Identifier: NCT03049410

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RoboticsUrinary Bladder NeoplasmsMaleHumansAgedFemaleCystectomyCost-Benefit AnalysisQuality of Life

Autor:innen und Institutionen

  • School of Health and Related Research, University of Sheffield, Sheffield, England.
  • PRICELESS SA (Priority Cost Effective Lessons for System Strengthening South Africa), School of Public Health, University of the Witwatersrand, Johannesburg, South Africa.
  • National Institute for Health Care Excellence, Manchester, England.
  • Division of Surgery & Interventional Science, University College London, London, England.
  • Department of Statistical Science, University College London, London, England.
  • Surgical & Interventional Trials Unit, Division of Surgery & Interventional Science, University College London, London, England.

Zitieren

APA

Dixon, S., Hill, H., Flight, L., Khetrapal, P., Ambler, G., Williams, N. R., Brew-Graves, C., Kelly, J. D., Catto, J. W. F., & iROC Study Team (2023). Cost-Effectiveness of Robot-Assisted Radical Cystectomy vs Open Radical Cystectomy for Patients With Bladder Cancer. JAMA Network Open, 6(6), e2317255. https://doi.org/10.1001/jamanetworkopen.2023.17255

Vancouver

Dixon S, Hill H, Flight L, Khetrapal P, Ambler G, Williams NR, et al. Cost-Effectiveness of Robot-Assisted Radical Cystectomy vs Open Radical Cystectomy for Patients With Bladder Cancer. JAMA Network Open. 2023;6(6):e2317255. doi:10.1001/jamanetworkopen.2023.17255

BibTeX
@article{Dixon2023,
  author = {Dixon, Simon and Hill, Harry and Flight, Laura and Khetrapal, Pramit and Ambler, Gareth and Williams, Norman R and Brew-Graves, Chris and Kelly, John D and Catto, James W F and iROC Study Team, iROC Study Team},
  title = {Cost-Effectiveness of Robot-Assisted Radical Cystectomy vs Open Radical Cystectomy for Patients With Bladder Cancer},
  journal = {JAMA Network Open},
  year = {2023},
  volume = {6},
  number = {6},
  pages = {e2317255},
  doi = {10.1001/jamanetworkopen.2023.17255}
}
Kostenlos starten →